Sarepta Therapeutics (SRPT) Posts Q1 Loss of 75c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.75), $0.05 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $6.09 million versus the consensus estimate of $3.45 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Sun Communities completes $1.03B sale of Park Holidays to Aermont
• UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals